Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/102129
Title: ErbB3 downregulation enhances luminal breast tumor response to antiestrogens
Author: Morrison, M.M.
Hutchinson, K.
Williams, M.M.
Stanford, J.C.
Balko, J.M.
Young, C.
Kuba, M.G.
Sánchez, V.
Williams, A.J.
Hicks, D.J.
Arteaga, C.L.
Prat, A.
Perou, C.M.
Earp, H.S.
Massarweh, S.
Cook, R.S.
Keywords: Càncer de mama
Receptors d'hormones
Estrògens
Medicaments antineoplàstics
Expressió gènica
Breast cancer
Hormone receptors
Estrogen
Antineoplastic agents
Gene expression
Issue Date: 1-Oct-2013
Publisher: American Society for Clinical Investigation
Abstract: Aberrant regulation of the erythroblastosis oncogene B (ErbB) family of receptor tyrosine kinases (RTKs) and their ligands is common in human cancers. ErbB3 is required in luminal mammary epithelial cells (MECs) for growth and survival. Since breast cancer phenotypes may reflect biological traits of the MECs from which they originate, we tested the hypothesis that ErbB3 drives luminal breast cancer growth. We found higher ERBB3 expression and more frequent ERBB3 gene copy gains in luminal A/B breast cancers compared with other breast cancer subtypes. In cell culture, ErbB3 increased growth of luminal breast cancer cells. Targeted depletion of ErbB3 with an anti-ErbB3 antibody decreased 3D colony growth, increased apoptosis, and decreased tumor growth in vivo. Treatment of clinical breast tumors with the antiendocrine drug fulvestrant resulted in increased ErbB3 expression and PI3K/mTOR signaling. Depletion of ErbB3 in fulvestrant-treated tumor cells reduced PI3K/mTOR signaling, thus decreasing tumor cell survival and tumor growth. Fulvestrant treatment increased phosphorylation of all ErbB family RTKs; however, phospho-RTK upregulation was not seen in tumors treated with both fulvestrant and anti-ErbB3. These data indicate that upregulation of ErbB3 in luminal breast cancer cells promotes growth, survival, and resistance to fulvestrant, thus suggesting ErbB3 as a target for breast cancer treatment.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1172/JCI66764
It is part of: Journal of Clinical Investigation, 2013, vol. 123, num. 10, p. 4329-4343
Related resource: http://dx.doi.org/10.1172/JCI66764
URI: http://hdl.handle.net/2445/102129
ISSN: 0021-9738
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
662594.pdf6.71 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.